H Abdollahi - PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman, Iran
I Shiri - PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-۱۲۱۱ Geneva ۴, Switzerland
J J Bevelacqua - PhD, Bevelacqua Resources, Richland, Washington, United States
A Jafarzadeh - PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman, Iran
A Rahmim - PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC, Canada
H Zaidi - PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-۱۲۱۱ Geneva ۴, Switzerland
S A R Mortazavi - MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
S M J Mortazavi - PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Physicians and scientists around the world are aggressively attempting to develop effective treatment strategies. The treatment goal is to reduce the fatality rate in ۱۵% to ۲۰% of individuals infected with SARS-CoV-۲ who develop severe inflammatory conditions that can lead to pneumonia, and acute respiratory distress syndrome. These conditions are major causes of death in these patients. Convalescent plasma (CP) collected from patients recovered from the novel corona virus disease (COVID-۱۹) has been considered as an effective treatment method for COVID-۱۹. Moreover, low-dose radiation therapy (LDRT) for COVID-۱۹ pneumonia was historically used to treat pneumonia during the first half of the ۲۰th century. The concept of LDRT for COVID-۱۹ pneumonia was first introduced in March ۲۰۲۰. Later scientists from Canada, Spain, United States, Germany and France also confirmed the potential efficacy of LDRT for treatment of COVID-۱۹ pneumonia. The rationale behind introducing LDRT as an effective treatment method for pneumonia in COVID-۱۹ patients is not only due to its anti-inflammatory effect, but also in optimization of the activity of the immune system. Moreover, LDRT, unlike other treatment methods such as antiviral drugs, does not have the key disadvantage of exerting a significant selective pressure on the SARS-CoV-۲ virus and hence does not lead to evolution of the virus through mutations. Given these considerations, we believe that a hybrid treatment including both CP and LDRT can trigger synergistic responses that will help healthcare providers in mitigating today’s COVID-۱۹ pandemic.

Low Dose Radiation, Radiotherapy, COVID-۱۹, Convalescent plasma, Anti-inflammatory responses, Immune system, Selective Pressure, Mutations